Armis Advisers’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Armis Advisers’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489K	Sell	8,313 -5,108	-38%	-$244K	0.04%	276
2026 Q1	$619K	Hold	13,421	–	–	0.06%	214
2025 Q4	$570K	Buy	+13,421	New	+$595K	0.06%	209
2025 Q3	–	Sell	-12,823	Closed	-$432K	–	423
2025 Q2	$432K	Sell	12,823 -25	-0.2%	-$792	0.03%	306
2025 Q1	$409K	Buy	12,848 +1,716	+15%	+$65.1K	0.04%	276
2024 Q4	$432K	Buy	+11,132	New	+$468K	0.05%	206

Other funds holding GNOM

SLT Holdings Scottsdale, Arizona $160M AUM 52.3% 1-Year Est. Return

Armis Advisers's GNOM Position: Q2 2026 in Review

Armis Advisers reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 38% in Q2 2026, selling an estimated $244K and leaving 8,313 shares worth $489K. The position accounts for 0.04% of the portfolio, ranked #276.

Armis Advisers first reported a position in GNOM in Q4 2024 and has held it in 6 quarters since. The position peaked at $619K in Q1 2026. 2 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Armis Advisers held 8,313 shares of Global X Genomics & Biotechnology ETF worth $489K as of Q2 2026.
Armis Advisers sold 5,108 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $244K.
Global X Genomics & Biotechnology ETF made up 0.04% of Armis Advisers's portfolio in Q2 2026, its #276 holding.
Armis Advisers first reported a position in Global X Genomics & Biotechnology ETF in Q4 2024 and has held it in 6 quarters since.
Armis Advisers's Global X Genomics & Biotechnology ETF position peaked at $619K in Q1 2026.
2 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.